Surrey Heartlands

Joint Formulary & PAD

Liothyronine sodium - Coma of Myxoedema

You are here : Home > Formulary Search > Liothyronine sodium - Coma of Myxoedema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous injection (IV)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

Evidence Review
Liothyronine CAPSULES - APC briefing paper - March 2022
Patient resource
Liothyronine caps - Patient Information - April 2022.pdf
Miscellaneous
SDCCG - Low value medicines implementation resources - Apr 2018

PAD Profile

ChemicalSubstance :
Liothyronine sodium
Indication :
Coma of Myxoedema
Group Name :
Keywords :
Hypothyroidism, underactive thyroid, L-T3, L-Tri-iodothyronine sodium, thyroid deficiency, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value, hypothyroid coma
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Liothyronine sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Coma of Myxoedema.

  • No records returned.

Committee Recommendations (1)

06 Apr 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

In March 2016 the APC (formerly PCN) agreed liothyronine (T3) as an option for the treatment of myxoedema coma and assigned it a RED traffic light status for this indication.

Licensed, bioequivalent liothyronine CAPSULES have entered the market at a considerably reduced price and the APC recommend that:

- the most cost effective preparation should be prescribed (currently capsules) in all new patients
- prescribers should consider switching existing patients from tablets to capsules - for discussion with the patient at next review

The APC noted the additional information provided in the Liothyronine capsules - briefing paper below